CorMDx is designed to support continuous heart monitoring in outpatient settings, especially for patients with limited hospital access. Unlike its predecessor, it transmits ECG data in real time and can be used for up to two years.
Peerbridge has launched two major trials: the 15,000-patient COR-Insight study to validate multi-condition detection, and the EF-ACT pivotal trial to assess left ventricular ejection fraction using ECG.
Darland plans to introduce CorMDx at about half the cost of competing devices, aligning with a fee-for-service reimbursement strategy that could financially benefit providers while improving patient outcomes.

Peerbridge Bets On At-Home Heart Monitoring With Rechargeable, Longer-Lasting ECG Patch

More from Clinical Trials